|
Ms. Grant is Cardiome's Vice President of Product Development for RSD1235. She is responsible for the overall management of the intravenous and oral RSD1235 programs. She has overseen development of RSD1235 IV from its initial toxicology studies as a clinical candidate in 1999, through to its current stage of development in Phase III and approaching NDA. Ms. Grant has also acted as Director of Finance and Administration and Director of Business Operations at Cardiome. Prior to joining Cardiome, Ms. Grant acted as business consultant to De Novo Enzyme Corporation and Coopers & Lybrand. Ms. Grant also worked in research and development, production, and quality assurance with Schering Agrochemicals U.K., Wellcome Biotechnologies U.K. and Serono Diagnostics U.K. respectively. Ms. Grant holds a B.Sc. (Hons) degree from Essex University, U.K. and an MBA degree from Simon Fraser University.
| 